Autopsy report · NCT04260802
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Cause of deathFunding or business
“Business Decision”
Life of this trial
- Registered 8 months before it started.
- Ran for about 5 years 1 month before it stopped.
- 73 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Ocellaris Pharma, Inc.
- Sponsor type
- Industry
- Conditions
- Cancer; Neoplasms; Metastatic Cancer; Triple Negative Breast Cancer; Gastric Cancer; Cervical Cancer
- Interventions
- OC-001; Drug: OC-001 in Combination with Avelumab
- Participants
- 73
- Sites
- 5
- Countries
- Canada
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.